已收盘 12-19 16:00:00 美东时间
+0.001
+0.21%
U.S. stocks traded higher this morning, with the Dow Jones index gaining around...
12-17 22:39
VYN202 was generally well tolerated with no drug-related adverse events Pharmacokinetic results demonstrated dose-dependent exposure of VYN202 in bloodPharmacodynamic activity observed on target engagement and
2024-09-12 20:13
HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 price target.
2024-08-15 17:57